Pfizer continues to be favored by investors due to its strong performance in the oncology drug market, highlighted by a 16.3% quarterly and 38.7% yearly sales increase of Padcev, driven by demand in combination with Merck's Keytruda. Despite recent FDA leadership changes, including the resignation of Commissioner Marty Makary, Pfizer's financial metrics remain attractive with a non-GAAP P/E ratio of 8.6x and a 6.8% dividend yield. The company’s promising drug pipeline and steady sales growth support a 'Strong Buy' rating from analysts, indicating confidence in its future performance.
Stocks priced under $30 often get overlooked, but Pfizer and Nu Holdings stand out with solid balance sheets and growth potential. Pfizer, a global biopharma giant, trades around $25 with a strong dividend yield and promising pipeline despite some re...
Michael Burry has invested in Pfizer, Molina Healthcare, and Halliburton for their strong cash flow, pricing power, and stable margins amid ongoing inflation. Pfizer offers a 6.66% dividend yield and growth potential as COVID impacts fade, trading at...
